NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Cognition Therapeutics, Inc. (CGTX) Stock Analysis

Cognition Therapeutics, Inc. (CGTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CGTX

$0.75

+$0.01 (+1.74%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CGTX with… →

CGTX Key Statistics

As of Oct 21, 2026
Trading
Open
$0.74
Previous Close
$0.73
Day's Range
0.74–0.76
52-Week Range
0.55–2.00
Volume
294.33K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.80
Valuation
Market Cap
$76.24M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.17
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$23.49M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
95.09M
1-Year Return
−57.82%
Dividend and dates
Avg Volume
482.63K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CGTX closed at $0.75, −57.82% over 1 year.

Cognition Therapeutics, Inc. (CGTX) has a market capitalization of $76.24M.

In fiscal 2025, CGTX reported revenue of $0.00.

CGTX Stock Return by Calendar Year

Cognition Therapeutics, Inc. (CGTX) return since Oct 2021: what $10,000 became

1 year
$10,000 $4,218
−57.82%
5 years
$10,000 $614
−93.86%
Since Oct 2021
$10,000 $585
−94.15%

If you had invested $10,000 in Cognition Therapeutics, Inc. (CGTX) at the close on October 8, 2021, the earliest close on record here, it would have been worth $585 at the close on October 21, 2026: −94.15% in total, −43.10% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−44.70%
2025+92.58%
2024−62.11%
2023−11.90%
2022−66.77%
2021 (partial year)−50.51%

As of October 21, 2026.

CGTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$23.49M—
2024$0.00−$33.97M—
2023$0.00−$25.79M—
2022$0.00−$21.40M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$24.39M−$23.49M—
2024$0.00—−$34.42M−$33.97M—
2023$0.00—−$25.92M−$25.79M—
2022$0.00—−$21.33M−$21.40M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cognition Therapeutics, Inc. (CGTX) is capitalised at $76.24M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 14 employees.

The most recent close on file for CGTX is $0.75, dated October 21, 2026. That is +$0.01 (+1.74%) against the previous close. Over the past 52 weeks the price has ranged from $0.55 to $2.00. The latest close sits 35.75% above that 52-week low.

Financial Health

In fiscal 2025, Cognition Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $23.49M. Earnings per share on a trailing basis come to −0.17.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 1.8. Annualized volatility over the trailing 5 years is 117.48%. The trailing one-year total return is −57.82%. Measured over 5 years, that is −42.77% a year compounded.

Growth & Income

The record shows no dividend for CGTX.

2026 is still running; the total return is −44.70% year to date. Across the complete calendar years on file, 2025 returned +92.58% and 2022 returned −66.77%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Cognition Therapeutics, Inc. (CGTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cognition Therapeutics, Inc. CGTX $76.24M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Cognition Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.

Visit website →